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Introduction {#sec1}
============

Cardiac morphogenesis results from the specification, differentiation, and migration of spatially and temporally distinct sets of cardiac precursor cells that give rise to the mature cardiac tissue. The first multipotent cardiogenic cells originate from the mesoderm formed at early stages of gastrulation when cells of the epiblast ingress to the primitive streak ([@bib12], [@bib13], [@bib18], [@bib23], [@bib38]). The mesoderm first expresses the markers BRACHYURY and FLK1 and subsequently the cardiogenic marker MESP1 ([@bib4], [@bib9], [@bib20], [@bib36]). The first (FHF) and second (SHF) heart fields then arise from the cardiogenic mesoderm to ultimately generate the atria, ventricles, and outflow tract of the nascent heart ([@bib7], [@bib14], [@bib33]). Both FHF and SHF progenitors express the transcription factors NKX2.5, TBX5, GATA4, MEF2C, and ISL1, although TBX5 is predominantly present in cells of the FHF, and Isl1 expression is a hallmark of SHF progenitors ([@bib27], [@bib33], [@bib40]). In mouse, the transcriptional modulator CITED2 is required for normal embryogenesis. Deletion of *Cited2* in the epiblast results in embryonic lethality associated with multiple cardiovascular defects ([@bib1], [@bib2], [@bib30], [@bib31], [@bib41], [@bib44]). Of important note, however, although *Cited2* is expressed in the early mesoderm ([@bib15]), conditional deletion of *Cited2* in BRACHYURY-expressing mesoderm cells or MESP1-expressing cardiogenic mesoderm progenitors did not significantly affect cardiac development ([@bib30]). In humans, mutations in the gene encoding CITED2 are associated with congenital heart disease ([@bib10], [@bib37]).

The specification and differentiation of cardiac progenitor cells (CPC) and mature cardiovascular cells during the in vitro differentiation of pluripotent stem cells recapitulate the cellular and molecular processes of embryonic development ([@bib3], [@bib4], [@bib5], [@bib11], [@bib17], [@bib22], [@bib24], [@bib27], [@bib33], [@bib39], [@bib43]). In mouse, an acute *Cited2* depletion reduces the self-renewal capacity of most embryonic stem cells (ESC), but a small population of *Cited2*-null ESC with apparent characteristics of undifferentiated cells adapt to the loss of *Cited2* ([@bib25], [@bib28]). Interestingly, *Cited2*-null ESC showed an impairment of differentiation, including cardiac commitment ([@bib28]). To better understand the role of *Cited2* at early stages of mouse ESC differentiation, we here employ *Cited2* loss- and gain-of-function approaches to examine the role of *Cited2* during cardiac differentiation. *Cited2* depletion at the onset of differentiation significantly impairs the expression of *Brachyury*, *Mesp1*, *Isl1*, *Gata4*, and *Tbx5*. Conversely, CITED2 overexpression stimulates the expression of these genes in undifferentiated ESC and promotes cardiac lineage commitment and differentiation. We further show that *Cited2* expression is highly associated with CPC populations, particularly cardiac progenitors of the SHF. Finally, we show that CITED2 is recruited to the promoter of the *Isl1* gene, and provide evidence that the human CITED2 and ISL1 proteins physically interact and synergize to promote cardiogenesis from ESC. Collectively our results show that *Cited2* is a key regulator of early cardiac lineage commitment and differentiation of ESC.

Results {#sec2}
=======

CITED2 Overexpression Promotes ESC Differentiation to Cardiac Lineages {#sec2.1}
----------------------------------------------------------------------

The knockout of *Cited2* in mouse ESC has been previously reported to impair cardiomyocyte differentiation ([@bib28]). To investigate whether the overexpression of CITED2 promotes ESC differentiation into cardiac lineages, we transfected undifferentiated mouse E14/T ESC with an episomal plasmid expressing a FLAG-tagged human CITED2 (flag-CITED2) or a control vector as previously described ([@bib25]). Upon differentiation, high levels of flag-CITED2 expression were detected in E14/T ESC (named E14T/flagCITED2 hereafter) at the onset of differentiation (day 0 \[D0\]) in comparison with the endogenous *Cited2* expression in control cells (named E14T/Control hereafter). However, the ectopic expression of flag-CITED2 in cells derived from E14T/flagCITED2 ESC rapidly declined during the first 3 days of differentiation, and returned to control levels by D6 ([Figure 1](#fig1){ref-type="fig"}A). An increase in the number of spontaneous contractile clusters (beating foci), marking the occurrence of terminal cardiomyocyte differentiation, was observed in cell cultures derived from E14T/flagCITED2 ESC in comparison with control cells ([Figure 1](#fig1){ref-type="fig"}B). Thus, the overexpression of flag-CITED2 significantly promoted cardiomyocyte differentiation, as confirmed by the elevated expression of cardiac structural genes, such as *α-cardiac myosin heavy chain* (*Myh6*) and *cardiac troponin T* (*cTnT*) transcripts detected in these cells in comparison with control cells ([Figure 1](#fig1){ref-type="fig"}C). The *vascular endothelial growth factor receptor 2* (*VegfR2*, a marker of endothelial differentiation) expression was also increased in cells derived from E14T/flagCITED2 ESC, while the expression of the *skeletal troponin I* (*sTnI*, a marker of skeletal muscle differentiation) was unaffected by the overexpression of flag-CITED2 ([Figure S1](#mmc1){ref-type="supplementary-material"}A), suggesting that flag-CITED2 overexpression supports ESC specification to cardiovascular cell lineages. To unravel the mechanism by which flag-CITED2 promoted the cardiac differentiation process, we assessed the expression of transcription factors known to play critical roles in the specification of ESC to cardiac lineages, particularly *Isl1*, *Gata4*, *Nkx2.5*, and *Tbx5*. Surprisingly, the overexpression of flag-CITED2 significantly increased the transcript levels of these factors in undifferentiated ESC (D0), and of *Isl1* and *Gata4* at D6 of differentiation ([Figure 1](#fig1){ref-type="fig"}D). The increase in the expression of Isl1 and Gata4 proteins was also detected in undifferentiated E14/T ESC overexpressing flag-CITED2 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Since CITED2 is a transcriptional modulator, we hypothesized that flag-CITED2 enhanced *Isl1*, *Gata4*, *Nkx2.5*, and *Tbx5* expression by a direct effect on their transcriptional regulatory regions. Therefore, we investigated by chromatin immunoprecipitation (ChIP) assays whether flag-CITED2 was recruited at the promoters of these factors. A significant enrichment of the *Isl1* promoter region was detected in E14T/flagCITED2 ESC extracts immunoprecipitated with an anti-flag antibody in comparison with E14T/Control extracts ([Figure 1](#fig1){ref-type="fig"}E). No difference of enrichment was observed for the exon 1 of *Isl1*, or for the *Nkx2.5*, *Gata4*, and *Tbx5* promoter fragments tested in the same conditions ([Figure 1](#fig1){ref-type="fig"}E). Interestingly, flag-CITED2 overexpression also significantly enhanced the occupancy of *Isl1* promoter and exon 1 by histones H3 trimethylated on lysine 4 (H3triMeK4), a mark of actively transcribed chromatin ([Figure 1](#fig1){ref-type="fig"}F). No enrichment of H3triMeK4 occupancy was detected at the promoters of *Nkx2*.5, *Gata4*, and *Tbx5* in the same extracts. Although these experiments do not enable us to rule out the presence of flag-CITED2 at other regulatory elements of *Nkx2.5*, *Gata4*, and *Tbx5* genes, they exposed its presence at the *Isl1* promoter. Moreover, the presence of flag-CITED2 at *Isl1* regulatory regions was also correlated with an increased recruitment of H3triMeK4 at these regions, suggesting that flag-CITED2 may exert a direct positive effect on the expression of *Isl1*.

Depletion of *Cited2* in ESC Differentiation Affects Cardiac Commitment {#sec2.2}
-----------------------------------------------------------------------

To further investigate the role of Cited2 in cardiac differentiation, we used C2^fl/fl^\[Cre\] ESC, which allow the conditional knockout of *Cited2* by supplementation of 4-hydroxytamoxifen (4HT) to the culture medium ([@bib25]). First, we analyzed *Cited2* expression kinetics by qPCR during the differentiation of control C2^fl/fl^\[Cre\] ESC ([Figures 2](#fig2){ref-type="fig"}A and 2B, black bars). The pattern of *Cited2* expression was biphasic, with a decrease of the transcript levels from D0 to D2 of differentiation, followed by an elevation from D3 onward ([Figure 2](#fig2){ref-type="fig"}B, black bars). A similar expression pattern for *Cited2* was also observed in E14T/Control cells ([Figure 1](#fig1){ref-type="fig"}A, black bars). Next, we examined *Cited2* expression in cells derived from C2^fl/fl^\[Cre\] ESC treated with 4HT at D0 of differentiation during 48 hr, and compared it with control cells derived from C2^fl/fl^\[Cre\] ESC treated with ethanol used as vehicle ([Figures 2](#fig2){ref-type="fig"}A--2C). *Cited2* depletion was incomplete during the time course of differentiation since *Cited2* transcripts remained detectable at D5 and D12 of differentiation in cells treated with 4HT, although these levels were significantly reduced in comparison with control cells ([Figure 2](#fig2){ref-type="fig"}B). Noticeably, the number of beating foci was reduced in cell cultures derived from ESC depleted of *Cited2* at D0 compared with control cells ([Figure 2](#fig2){ref-type="fig"}D). The decline of *Myh6* and *cTnT* transcripts expression and the reduced number of cells expressing cTNT protein in cultures treated with 4HT supported the requirement of *Cited2* expression for ESC differentiation into cardiac lineages ([Figures 2](#fig2){ref-type="fig"}E and 2F). To evaluate the expression and organization of sarcomeric proteins in cardiomyocytes, we performed fluorescent immunodetection of the α-ACTININ and MYOSIN HEAVY CHAIN (MF20) proteins in cells at D10 of differentiation derived from C2^fl/fl^\[Cre\] ESC treated either with ethanol or 4HT at D0 ([Figure 2](#fig2){ref-type="fig"}G). Approximately 25%--30% of the cells derived from control C2^fl/fl^\[Cre\] ESC were positively stained for α-ACTININ or MF20 and presented some degree of organization of the sarcomeric apparatus ([Figures 2](#fig2){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}C). The depletion of *Cited2* by treatment of C2^fl/fl^\[Cre\] ESC with 4HT resulted in the decline of α-ACTININ and MF20 protein detection, and in the diminution of the number of cells stained for α-ACTININ or MF20 in comparison with the control cells ([Figures 2](#fig2){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}C). Together, these observations were consistent with the requirement of *Cited2* for ESC-derived cardiogenesis. In contrast, *Cited2* depletion did not significantly alter the expression of *Nestin* and *βIII-Tubulin* (markers of neural cells, ectoderm origin) and the α-fetoprotein (hepatic marker, endoderm origin). *Cited2* depletion did result in a reduction of *Foxa2* (endoderm and hepatocyte marker) expression at D12 ([Figure 2](#fig2){ref-type="fig"}F), consistent with the role played by *Cited2* in liver development ([@bib35]). Interestingly, the treatment of C2^fl/fl^\[Cre\] ESC with 4HT at D2 of differentiation only mildly affected the emergence of beating clusters, while no alteration was observed after 4HT treatment at D4 or D6 of differentiation in comparison with control cells ([Figure 2](#fig2){ref-type="fig"}D). These observations suggest that *Cited2* supports ESC specification to cardiomyocyte lineages during the first 2--3 days of differentiation. In agreement with these results, we showed that *Cited2*-null C2^Δ/Δ^\[LA11\] ESC devoid of *Cited2* expression ([@bib25]) have a reduced capacity to generate cardiac contractile clusters when compared to control C2^fl/fl^ ESC ([Figure 3](#fig3){ref-type="fig"}A). To confirm that the cardiac differentiation defects observed in *Cited2*-depleted cells were due to the loss of *Cited2* expression, C2^fl/fl^\[Cre\] ESC treated with 4HT at D0 were transduced with a human recombinant CITED2 protein (sharing interchangeable functions with the mouse protein in cardiac development \[[@bib10], [@bib25]\]) fused at its N-terminal domain with a stretch of eight arginines (termed 8R-CITED2). Polyarginine peptides are transduction domains that enable proteins to cross the cellular membrane when applied to the culture medium ([@bib29]). The purified 8R-CITED2 added into the culture medium crossed the cellular membrane, translocated into the nucleus of *Cited2*-null ESC, and interfered with the high-affinity binding of overexpressed human CITED2 protein to the CH1 domain of p300 ([@bib16]), suggesting that 8R-CITED2 is functional ([Figure S2](#mmc1){ref-type="supplementary-material"}). Interestingly, the supplementation of 8R-CITED2 at D2 of differentiation in the culture medium of C2^fl/fl^\[Cre\] ESC treated with 4HT at D0 restored the emergence of beating foci to control levels ([Figure 3](#fig3){ref-type="fig"}B). These results argue that the cardiogenic defects of *Cited2*-depleted ESC are caused by the loss of Cited2 expression. Altogether, these observations suggested that *Cited2* is important for early events of ESC commitment to cardiac cell lineages.

*Cited2* Is Necessary for the Expression of Genes Specifying Cardiac Mesoderm and Cardiac Progenitors {#sec2.3}
-----------------------------------------------------------------------------------------------------

During early differentiation, the expression of pluripotency markers *Oct4*, *Sox2*, and *Nanog* was silenced with comparable rates in control and 4HT-treated cells ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Thus, a misregulation of pluripotency factors cannot account for the deficiency in cardiac differentiation of *Cited2*-depleted ESC. Next, we assessed the expression of genes marking early (cardiac) mesoderm induction such as *Activin A*, *Nodal*, *Brachyur*y, and *Mesp1* ([Figures 3](#fig3){ref-type="fig"}C and 3D). No significant alteration in *Nodal* and *Activin A* expression was observed at D2 and D3 in control and D0 *Cited2*-depleted cell cultures ([Figure 3](#fig3){ref-type="fig"}C). In contrast, *Brachyury* expression was significantly reduced at D3 but restored at D5, and *Mesp1* expression was markedly downregulated at D3 and D5 ([Figure 3](#fig3){ref-type="fig"}D). The decrease of *Brachyury* and *Mesp1* expression is in agreement with a previous report that had indicated that *Cited2* supports mesoderm differentiation ([@bib28]) and with our observations suggesting that CITED2 is important during the first 2--3 days of ESC differentiation ([Figure 2](#fig2){ref-type="fig"}). In addition, the expression of *Isl1*, *Gata4*, and *Tbx5* transcripts, as well as the expression of Isl1 and Gata4 proteins, was reduced at D5 of differentiation in *Cited2*-depleted cells ([Figures 3](#fig3){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}B). *Isl1* expression levels were also lower at D2 while *Tbx5* expression remained decreased at D12 ([Figure 3](#fig3){ref-type="fig"}E). The expression of *Nkx2.5* was unchanged in similar conditions ([Figure 3](#fig3){ref-type="fig"}E).

Since the treatment of C2^fl/fl^\[Cre\] ESC with 4HT at D0 only achieved a partial knockout of *Cited2* ([Figure 2](#fig2){ref-type="fig"}B), the remaining *Cited2* expression may confound the effects of *Cited2* depletion on gene expression. Therefore, to clarify the consequences of *Cited2* loss on *Brachyury*, *Mesp1*, *Isl1*, *Gata4*, *Nkx2.5*, and *Tbx5* expression, we differentiated control C2^fl/fl^ ESC and *Cited2*-null C2^Δ/Δ^\[LA11\] ESC, which are impaired for cardiac differentiation ([Figure 3](#fig3){ref-type="fig"}B). In this context *Gata4* expression was not altered, but a significant downregulation of *Brachyury*, *Mesp1*, *Isl1*, *Nkx2.5*, and *Tbx5* expression was detected in cultures derived from C2^Δ/Δ^\[LA11\] ESC at D5 of differentiation in comparison with control cells ([Figure 3](#fig3){ref-type="fig"}F). Interestingly, supplementation of C2^Δ/Δ^\[LA11\] ESC-derived cells at D2 of differentiation with 8R-CITED2, stimulated *Brachyury*, *Mesp1*, *Isl1*, *Nkx2.5*, and *Tbx5* expression at D5 of differentiation with *Isl1* expression being restored to control levels ([Figure 3](#fig3){ref-type="fig"}F). This observation further argues for a mechanistic link between *Cited2* and *Isl1* expression levels. To determine whether endogenous CITED2 is recruited to the promoter of *Isl1* at D5 of differentiation, we performed ChIP using anti-CITED2 and control polyclonal antibodies with cellular extracts prepared from cells derived from E14/T ESC ([Figure 3](#fig3){ref-type="fig"}G). Endogenous CITED2 was specifically detected at the promoter region of *Isl1* in these cells at D5 of differentiation, suggesting that CITED2 binds to *Isl1* promoter in cells derived from ESC. Together, these observations suggested that *Cited2* not only supports mesoderm induction but also regulates the expression of key genes during CPC specification including *Isl1*.

*Cited2* Is Expressed in Cardiac Progenitors {#sec2.4}
--------------------------------------------

Since *Cited2* expression was associated with the expression of CPC markers, such as *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5* ([Figures 1](#fig1){ref-type="fig"}D, [3](#fig3){ref-type="fig"}E, and 3F), we sought to determine whether *Cited2* was expressed in CPC. For this purpose, we used mouse AD2 ESC harboring the dsRed (R) and eGFP (G) genes under the control of the *Mef2c*/AHF and *Nkx2.5* cardiac-specific enhancers, respectively ([@bib14]). The differentiation of AD2 ESC originates R^+^/G^−^, R^−^/G^+^, R^+^/G^+^, and R^−^/G^−^ cell populations equivalent to CPC of the pharyngeal mesoderm, FHF CPC, committed ventricular CPC of the SHF, and non-cardiac cells, respectively ([@bib14]). *Cited2* expression, assessed by qPCR in AD2-derived cell populations isolated by fluorescence-activated cell sorting at D6 of differentiation, revealed that *Cited2* transcripts were enriched in all CPC populations when compared with R^−^/G^−^ cells, with higher levels of expression observed in R^+^/G^+^ cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). The expression of *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5* in the distinct CPC populations ([Figure S1](#mmc1){ref-type="supplementary-material"}E) was as previously reported ([@bib14]). To determine whether Cited2 promotes the emergence of CPC, 2 days prior to differentiation we transiently transfected AD2 ESC with either a control vector or the plasmid expressing flag-CITED2 ([Figure 4](#fig4){ref-type="fig"}C). The expression of flag-CITED2 stimulated endogenous *Isl1* expression at D0, as observed in E14/T cells ([Figure 1](#fig1){ref-type="fig"}D), and significantly increased the number of R^+^/G^+^ cells derived from AD2 ESC differentiation at D6 ([Figure 4](#fig4){ref-type="fig"}D). In addition, the expression profile of *Cited2* in cardiac progenitors in vivo was assessed in CPC populations isolated from embryonic day 9.5 (E9.5) hearts of mouse transgenic embryos harboring the *dsRed* and *eGfp* genes ([@bib14]). Interestingly, *Cited2* expression was enriched in the R^+^/G^+^ subpopulation simultaneously expressing *Isl1* and *Nkx2.5* ([Figure 4](#fig4){ref-type="fig"}E). Collectively, these observations indicated that *Cited2* is expressed in FHF and SHF CPC derived from ESC.

CITED2 and ISL1 Proteins Interact and Synergize to Enhance Cardiac Differentiation {#sec2.5}
----------------------------------------------------------------------------------

ISL1 is a protein with two LIM domains located at its N-terminal domain, both important for SHF expansion and morphogenetic control of cardiogenesis ([@bib42]). Since CITED2 binds to the LIM domain of the transcription factor LHX2 ([@bib19]), we hypothesized that ISL1 and CITED2 proteins might physically interact. We therefore synthesized a ^35^S-labeled myc-tagged full-length human ISL1 protein (myc-ISL1) by coupled in vitro transcription-translation, and tested for its ability to bind to a glutathione S-transferase (GST)-CITED2 fusion protein ([Figure 5](#fig5){ref-type="fig"}A). Myc-ISL1 interacted specifically with GST-CITED2 full-length protein and the C-terminal residues of CITED2 (amino acids 66--270). It also interacted weakly with CITED2 N-terminal residues (amino acids 2--214). To confirm the interaction between CITED2 and ISL1 in cells, we used the anti-FLAG antibody to immunoprecipitate protein extracts from HEK293T cells expressing either myc-ISL1 alone or myc-ISL1 and flag-CITED2. Immunopurified proteins were then analyzed by western blot with anti-ISL1 and anti-FLAG antibodies ([Figure 5](#fig5){ref-type="fig"}B). Myc-ISL1 was co-immunoprecipitated with flag-CITED2, implying that ISL1 and CITED2 were in protein complexes in HEK293T cells. We also visualized ISL1-CITED2 interaction in living cells using vectors expressing either ISL1 in fusion with the N-terminal domain of the fluorescent protein VENUS (VEN-ISL1), CITED2 in fusion with the C-terminal domain of VENUS (VEC-CITED2), or control vectors to perform bifluorescence complementation (BiFC) assays ([@bib32]). The co-transfection of VEN-ISL1 and VEC-CITED2 in E14/T cells resulted in a specific detection of fluorescence, confirming that ISL1 and CITED2 associate in these cells ([Figures 5](#fig5){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}).

To test the functional significance of CITED2-ISL1 interaction, we co-transfected Hep3B cells with vectors expressing myc-ISL1 and flag-CITED2 together with a reporter construct harboring *luciferase* under the control of a composite regulatory region containing the *Mef2c* cardiac-specific enhancer, which is a direct target of Isl1 ([@bib42]). The transfection of myc-ISL1 vector increased the reporter activity, and this was further enhanced by co-transfection of flag-CITED2 vector ([Figure 5](#fig5){ref-type="fig"}D). These observations provide evidence that myc-ISL1 and flag-CITED2 synergize to stimulate the activity of an ISL1-responsive reporter.

To determine whether CITED2 and ISL1 cooperate to promote ESC differentiation toward cardiac cell fate, the number of beating foci originating from undifferentiated E14/T ESC expressing VEC-CITED2 and VEN-ISL1 individually or in combination was evaluated at D8, D10, and D12 of differentiation ([Figure 5](#fig5){ref-type="fig"}E). The transfection of VEC-CITED2 or VEN-ISL1 individually led to the emergence of beating foci at similar levels, while the co-transfection of VEC-CITED2 and VEN-ISL1 significantly increased the number of contractile foci at D12. Altogether, these observations provide evidence for a physical and functional interaction between ISL1 and CITED2 that promotes ESC differentiation toward cardiac cell lineages.

Discussion {#sec3}
==========

In this study, we show that *Cited2* is required for early cardiac commitment of mouse ESC, in agreement with a previous study ([@bib28]). We and others have demonstrated that *Cited2* expression promotes mouse ESC self-renewal ([@bib10], [@bib25], [@bib34]). Interestingly, we show that the deletion of *Cited2* in ESC or depletion of *Cited2* at the onset of differentiation impairs cardiac lineage commitment. Remarkably, we determine that endogenous expression of *Cited2* transcripts is biphasic during ESC differentiation, starting with a decrease from D0 to D2. This decline of *Cited2* expression upon differentiation might be necessary for ESC to switch from a non-permissive to a permissive differentiation state. In a second phase, *Cited2* expression increases from D3 of differentiation onward, implying that *Cited2* might be required for subsequent differentiation processes. This is corroborated by the rescue of the cardiac differentiation defects in *Cited2*-depleted ESC with the supplementation of the recombinant CITED2 protein to the cells at D2 of differentiation, a day before the levels of endogenous *Cited2* start to increase during differentiation.

The impairment of cardiac differentiation resulting from *Cited2* depletion at the onset of ESC differentiation may be due to a consequent downregulation of *Brachyury* and *Mesp1* expression. The decrease of *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5* expression that we observed in *Cited2*-depleted cells at D5 of differentiation, which corresponds to the time when CPC emerge, might be a consequence of *Mesp1* downregulation, since these genes are activated by MESP1 to promote cardiogenesis and CPC specification during cardiac development and ESC differentiation ([@bib4], [@bib13]). On the other hand, we show that *Cited2* expression is enriched in CPC, and CITED2 protein is recruited to *Isl1* promoter at D5 of differentiation during CPC specification. This suggests that CITED2 may play a role in CPC specification, proliferation, and/or differentiation. In agreement with this hypothesis, flag-CITED2 overexpression promoted both the emergence of CPC and terminal cardiomyocyte differentiation from ESC, and increased *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5* expression in undifferentiated ESC. Fluctuations in the expression of genes encoding transcription factors with capacities to instruct lineage specification have been evidenced in undifferentiated pluripotent ESC and, in accordance with the transcripts expressed, subsets of ESC might be prone to undergo particular differentiation programs ([@bib26]). The overexpression of CITED2 in undifferentiated ESC might specify and promote CPC and cardiac differentiation by raising the expression of the pro-cardiogenic factors *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5*. Interestingly, the transdifferentiation of human dermal fibroblasts into cardiac progenitors by expression of MESP1 and ETS2 has been shown to stimulate the expression of CITED2 ([@bib21]), suggesting that CITED2 may play a role in cardiac progenitor specification and/or functions. Therefore, CITED2 overexpression might be instrumental for specification of CPC and cardiomyocyte differentiation from pluripotent stem cells.

We also provided evidence for a privileged regulatory interaction between *Cited2* and *Isl1*. Indeed, our ChIP assays show that CITED2 is specifically recruited at the *Isl1* promoter. Furthermore, supplementation of *Cited2*-null ESC with CITED2 recombinant protein restores the expression of *Isl1* to normal levels at D5 of ESC differentiation. In addition, ESC overexpressing flag-CITED2 are enriched for H3triMeK4 at the *Isl1* regulatory elements, which marks transcriptionally active chromatin. The mechanisms by which flag-CITED2 overexpression contribute to the enrichment of H3triMeK4 at the *Isl1* loci and increase *Gata4* and *Nkx2.5* expression in undifferentiated ESC remain to be elucidated. Interestingly, at the protein level we demonstrated that ISL1 and CITED2 interact, delineated the amino acids 66--214 of CITED2 as part of the ISL1 interacting domain, and by transient transfection assays established that CITED2 increased ISL1-mediated *Mef2c*-enhancer activity and that ISL1 and CITED2 have a synergistic effect on cardiac cells derived from ESC. The exact molecular mechanism by which CITED2 and ISL1 cooperate in cardiac specification remains to be clarified, but it has been recently demonstrated that in mouse embryonic hearts and cardiac progenitors ISL1 interacts with p300 to selectively promote H3 acetylation at the *Mef2c* promoter ([@bib45]). Since CITED2 interacts strongly with p300, it would be of interest to determine whether CITED2 cooperates with p300 to promote its functional interaction with ISL1.

Altogether, our results indicated that *Cited2* contributes to the expression of a subset of pivotal cardiopoietic genes involved in mesoderm and cardiac progenitor specification ([Figure 5](#fig5){ref-type="fig"}F). During mouse embryonic development, *Cited2* expression was detected in the early mesoderm- and cardiac-derived structures ([@bib15]), but rather surprisingly a *Brachyury*/*T-Cre* or *Mesp1-Cre* conditional *Cited2* knockout only resulted in infrequent and minor heart developmental defects of mouse embryos, while *Cited2* knockout in the epiblast consistently caused heart malformations ([@bib1], [@bib30]). In the present report, we show that *Cited2* depletion at the onset of differentiation causes the most severe impact on cardiac differentiation, and results also in the impairment of *Brachyury* and *Mesp1* expression at D3. Interestingly, the cardiogenic defects due to the loss of *Cited2* expression at D0 were reversed by supplementation of the 8R-CITED2 at D2 of differentiation. On the other hand, *Cited2* depletion at later time points (D2, D4, and D6) had little or no effect on cardiogenesis. Together, these observations indicate that Cited2 function is important for early commitment of ESC to mesoderm and/or cardiac specification, or at least contribute to the correct expression of *Brachyury* and *Mesp1*, or other genes crucial for these processes. Therefore, the lack of a strong phenotype in *Brachyury*/*T-Cre* and *Mesp1-CreCited2* conditional knockout might be because the depletion of *Cited2* in these embryos was triggered after *Brachyury* and *Mesp1* were activated and after the requirement for *Cited2*. Of particular interest, we show that CITED2 stimulates the expression of *Isl1*, a marker of SHF cardiac progenitors, and binds to its promoter at the time of CPC specification. We also show that *Cited2* expression is enriched in SHF cardiac progenitors derived either from ESC or mouse E9.5 embryonic hearts. Moreover, *Cited2*-null embryos display a variety of cardiac developmental defects such as ventricular septal defects with overriding aorta or double-outlet right ventricle, outflow tract defects, and transposition of the great arteries, which may result from anomalies of SHF and cardiac neural crest cell progenitors known to express ISL1 ([@bib1], [@bib6]). Therefore, CITED2 and ISL1 may also interact during heart development and play a critical role for the fulfillment of CPC functions in this process. It would be of interest to investigate the contribution of the CITED2-ISL1 interaction in CPC functions both in vitro and in vivo.

Experimental Procedures {#sec4}
=======================

All mice were cared for within the Animal Care facilities of the Massachusetts General Hospital under the supervision of an active and functioning Subcommittee on Research Animal Care (SRAC), which serves as the Institutional Animal Care and Use Committee (IACUC) as required by the Public Health Service (PHS) Policy on Humane Welfare Regulations.

Embryonic Stem Cells, Culture Conditions, and Isolation of Cardiac Progenitor Populations {#sec4.1}
-----------------------------------------------------------------------------------------

Apple D2 (AD2), C2^fl/fl^, C2^Δ/Δ^\[LA11\], C2^fl/fl^\[Cre\], and E14/T mouse ESC lines were described previously, and were cultured on gelatin-coated plates in undifferentiating medium supplemented with LIF ([@bib8], [@bib14], [@bib25]). All ESC lines were differentiated using the hanging-drop method in medium containing 20% fetal bovine serum without LIF supplementation (differentiation medium).

Flow Cytometry Analysis {#sec4.2}
-----------------------

For detection of cardiac troponin I type 3 (cTNT), cells were fixed with 0.5% paraformaldehyde for 20 min at room temperature, blocked, and permeabilized with PBS containing 0.5% BSA and 0.1% saponin for 5 min at 4°C, washed with blocking solution, and incubated for 1 hr at 4°C with a monoclonal anti-mouse cTNT antibody (NB110-2546, Novus Biologicals) at a 1:800 dilution followed by 1 hr of incubation at 4°C with a secondary goat anti-mouse immunoglobulin G conjugated with Alexa 488 (A21202, Life Technologies) used at 1:2,000 dilution. Flow cytometry analyses were performed on a FACSCalibur (BD Biosciences) operating at 488 nm excitation with standard emission filters. Baseline of noise fluorescence was established with cells incubated only with the secondary antibody.

Real-Time qPCR {#sec4.3}
--------------

Total RNA isolation, cDNA synthesis, and qPCR assays were carried out as previously described ([@bib25]) with the primers listed in [Table S1](#mmc1){ref-type="supplementary-material"}. The primer set designated Cited2 detects both mouse endogenous *Cited2* and human exogenous *flag-CITED2*. For the selection of reliable reference genes, the expression of three reference genes, *hprt*, *Gapdh*, and *18S* was tested in samples prepared from C2^fl/fl^\[Cre\] and E14/T ESC at different time points of the differentiation ([Figure S3](#mmc1){ref-type="supplementary-material"}E). *Gapdh* and *18S* showed a very consistent expression across the differentiation process of both cell types. We opted for the normalization of gene expression levels to *Gapdh*, as previously performed ([@bib25]).

Immunochemistry {#sec4.4}
---------------

Immunocytochemistry was performed with C2^fl/fl^\[Cre\] ESC treated with ethanol or 4HT at D0 and differentiated for 10 days. Western blotting assays were performed using 20 μg of whole-cell lysates prepared from the indicated mouse ESC as previously described ([@bib25]).

Chromatin Immunoprecipitation Assays {#sec4.5}
------------------------------------

ChIP experiments and enrichment of target genomic elements by qPCR were performed as previously described ([@bib25]) using the primers listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

Production and Transduction of the Recombinant 8R-CITED2 Protein {#sec4.6}
----------------------------------------------------------------

Full-length human CITED2 cDNA and an oligonucleotide encoding eight arginines (8R) were cloned into the pGEX6P1 vector (GE Healthcare Life Sciences) to express a chimeric protein consisting of the GST in fusion with the 8R domain and CITED2 (termed GST-8R-CITED2, [Figure S2](#mmc1){ref-type="supplementary-material"}). Newly constructed plasmids were validated by sequencing and the expression of fusion proteins tested by western blot ([Figure S2](#mmc1){ref-type="supplementary-material"}). Details of plasmid construction and protein purification are available upon request.

Protein Interactions and Plasmids {#sec4.7}
---------------------------------

For in vitro binding assays, GST-CITED2 fusion proteins and in vitro translated myc-ISL1 were prepared as previously described ([@bib32]). Myc-ISL1 expression plasmid was constructed in pcDNA3 (Invitrogen) with an amino-terminal myc epitope tag. Plasmids expressing flag-CITED2 and pPyCAGIP were previously described ([@bib10]). For BiFC assays, plasmids expressing VEC-CITED2, VEN-p300CH1, VEC-GAL4, VEN-GAL4, and the VEN vector were described elsewhere ([@bib32]). The plasmid VEN-ISL1 expressing VEN (amino acid residues 1--155 of the VENUS fluorescent protein) in fusion with ISL1 was obtained by subcloning ISL1 cDNA fragment of the Myc-ISL1 expression plasmid into the VEN vector in frame with the VEN domain. All newly constructed plasmids were validated by sequencing and the expression of fusion proteins tested by western blot ([Figure S3](#mmc1){ref-type="supplementary-material"}). Details of plasmid construction are available upon request. For co-immunoprecipitation assays, ∼0.4 mg of whole-cell extracts from HEK293T cells transfected with flag-CITED2 expression vector alone or together with myc-ISL1 vector were used.

Reporter Assays {#sec4.8}
---------------

Hep3B cells, a human hepatocellular carcinoma cell line with low levels of endogenous CITED2, were plated in 24-well plates at 2.5 × 10^4^ cells per well and transfected the following day using Lipofectamine 2000 (Invitrogen) with Mef2c-luc reporter ([@bib42]) and expression vectors. CMV-*lacZ* plasmid was co-transfected in all experiments, and both LUCIFERASE and β-GALACTOSIDASE activities measured as previously described ([@bib25]).

Statistical Analysis {#sec4.9}
--------------------

Statistical significance was determined by two-tailed Student\'s t tests assuming unequal variance. p Values of \<0.05 were considered statistically significant.
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![Ectopic Expression of Human CITED2 Promotes Cardiac Differentiation\
(A) Relative expression of flag-Cited2 during differentiation, determined by qPCR in E14/T ESC transfected with a plasmid expressing FLAG-tagged CITED2 (flag-CITED2) or the control empty plasmid (vector). NS, not significant.\
(B) Number of colonies with beating foci counted at the indicated days of differentiation in cells treated as described in (A).\
(C) Expression levels of *Myh6* and *cTnT* determined by qPCR at D6 and D12 of differentiation in cells treated as described in (A).\
(D) Expression of *Isl1*, *Gata4*, *Nkx2.5*, and *Tbx5* at D0, D3, D6, and D12 of differentiation in E14/T-derived cell extracts prepared as described in (A).\
(E) Top: diagram of the mouse *Isl1* genomic contig showing the transcriptional start site (arrow), exon 1 (gray box), and positions of PCR primers (arrow heads) used in ChIP assays. Bottom: enrichment of *Isl1* promoter (Isl1-A) and exon 1 (Isl1-B), and *Nkx2.5*, *Gata4*, and *Tbx5* promoters in extracts of undifferentiated E14/T ESC overexpressing flag-CITED2 or control cells by ChIP assays with anti-FLAG monoclonal antibody.\
(F) Enrichment of the genomic regions of *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5* in ChIP assays with extracts and primers described in (E), using an anti-histone H3triMeK4-specific antibody.\
Results are presented as the mean ± SEM of three independent biological experiments.](gr1){#fig1}

![*Cited2* Is Important for Early Steps of Cardiac Differentiation\
(A) Timeline depicting the protocol used for differentiation of mouse ESC from D0 onward. The time of ethanol or 4HT treatment and the days of beating activity assessment are indicated.\
(B) Expression of *Cited2* determined by qPCR at D0, D2, D3, D5, and D12 of differentiation in cells derived from C2^fl/fl^\[Cre\] ESC treated at D0 with 4HT or ethanol for 48 hr.\
(C) CITED2 protein levels determined by western blotting in extracts from C2^fl/fl^\[Cre\] ESC, 48 hr after incubation with ethanol or 4HT. Loading in each lane was monitored by detection of β-TUBULIN.\
(D) Percentage of colonies with beating foci derived from C2^fl/fl^\[Cre\] ESC treated with ethanol or 4HT at D0, D2, D4, and D6 of differentiation.\
(E) Quantification by flow cytometry of cells expressing cTNT at D12, treated as described in (B). The percentage of cells expressing cTNT over the total number of cells is indicated.\
(F) Expression levels determined by qPCR of *Myh6*, *cTnT*, *Foxa2*, α-fetoprotein (*Afp*), *Nestin*, and *βIII-tubulin* (*βIII-tub.*) at D12 of differentiation in cells treated as described in (B).\
(G) Immunofluorescent detection of α-ACTININ (left panels, red staining) and MYOSIN HEAVY CHAIN MF20 (right panels, red staining) in C2^fl/fl^\[Cre\] ESC-derived cells at D10 of differentiation, after treatment for 2 days with ethanol (upper panels) or 4HT (lower panels) at D0. Nuclei were counterstained using DAPI (blue), and cells were examined on at 100× magnification.\
Results in (B), (D), (E), and (F) are presented as the mean ± SEM of three independent biological experiments.](gr2){#fig2}

![Loss of *Cited2* Impairs Expression of Genes Specifying Cardiac Mesoderm\
(A) Percentage of colonies with beating foci derived from C2^fl/fl^ and C2^Δ/Δ^\[LA11\] ESC at D8 and D10 of differentiation.\
(B) Percentage of colonies with beating foci counted at 8 and 10 days after the initiation of differentiation in cell cultures derived from C2^fl/fl^\[Cre\] ESC treated with ethanol or 4HT at D0 of differentiation, and with 4HT at D0 of differentiation and supplemented with recombinant 8R-CITED2 protein at D2 of differentiation (4HT + 8R-CITED2).\
(C) Expression of *Activin A* and *Nodal* determined by qPCR at D2 and D3 of differentiation in cultures derived from C2^fl/fl^\[Cre\] ESC treated with 4HT or ethanol at D0 for 48 hr.\
(D) Expression of mesoderm markers (*Brachyury* and *Mesp1*) at D2, D3, D5, and D12 of differentiation in cells generated from C2^fl/fl^\[Cre\] ESC treated as described in ([Figure 2](#fig2){ref-type="fig"}B).\
(E) Expression of *Isl1*, *Gata4*, *Nkx2.5*, and *Tbx5* in cell cultures as described in (D). The inserts for *Isl1* and *Tbx5* detail the expression of these genes at D5 and D3, respectively.\
(F) Relative expression of *Brachyury*, *Mesp1*, *Isl1*, *Gata4*, *Nkx2.5*, and *Tbx5* determined by qPCR at D5 of differentiation in cultures derived from untreated C2^fl/fl^ and C2^Δ/Δ^\[LA11\] ESC, and C2^Δ/Δ^\[LA11\] ESC supplemented with the recombinant 8R-CITED2 protein (C2^Δ/Δ^\[LA11\] + 8R-CITED2) at D2 of differentiation for 48 hr. Gene expression in C2^fl/fl^ ESC was set to 1.\
(G) Enrichment of *Isl1* genomic regions in extracts of E14/T ESC-derived cells at D5 by ChIP assays with anti-CITED2 or control (immunoglobulin G) polyclonal antibodies.\
Results are presented as the mean ± SEM of three independent biological experiments.](gr3){#fig3}

![CITED2 Is Expressed in Cardiac Progenitors and its Overexpression Promotes Cardiac Progenitor Specification\
(A) Representative flow cytometry plots of the R+/G^−^, R^−^/G+, R+/G+, and R^−^/G^−^ cell populations derived from AD2 ESC at D6 of differentiation. Numbers indicate percentage of cells within each gate.\
(B) Relative expression of *Cited2* determined by qPCR in cell populations derived from AD2 at D7 differentiation. Expression of the indicated genes is reported relative to their expression in non-cardiac cells R^−^/G^−^ set at 1.\
(C) Relative expression of ectopic CITED2 and endogenous *Isl1* determined by qPCR at D0 and D5 of differentiation, in AD2 ESC transiently transfected with a plasmid expressing flag-CITED2 or a control vector. flag-*Cited2* and *Isl1* expressions are relative to their expression in cells transfected with the control vector set at 1.\
(D) Quantification, at D6 of differentiation by flow cytometry, of R+/G^−^, R^−^/G+, R+/G+, and R^−^/G^−^ populations derived from AD2 ESC transfected with a plasmid expressing flag-CITED2 or a control vector. Cell numbers are reported relative to background determined at the onset of differentiation, which was set at 1.\
(E) Relative expression of *Cited2*, *Isl1*, and *Nkx2.5* determined by qPCR in embryonic cardiac progenitor populations at E9.5.\
Results in (B) and (E) are presented as the mean ± SEM of three independent biological experiments, while results in (C) and (D) are presented as the mean ± SEM of two independent biological experiments each performed in technical triplicates.](gr4){#fig4}

![CITED2 Binds to ISL1 and Both Synergize to Enhance Cardiac Differentiation\
(A) Binding of ^35^S-labeled myc-ISL1 protein either to GST alone or GST fused to full-length CITED2 (GST-CITED2, amino acid residues 2--270), the N-terminal fragment GST-CITED2(2--214), or the C-terminal fragment GST-CITED2(66--270). Ten percent of labeled myc-ISL1 used for the binding assay was loaded as the input. Top panel: autoradiogram showing the binding of ^35^S-labeled ISL1 to GST and GST-CITED2 proteins. Bottom panel: Coomassie blue stain of the gels showing relative amounts of GST and GST-CITED2 proteins.\
(B) Whole-cell extracts from HEK293T cells expressing myc-ISL1 alone or in combination flag-CITED2 immunoprecipitated (IP) with an anti-FLAG antibody, and proteins detected by western blot (WB) with anti-ISL1 and anti-FLAG antibodies. Five percent of the input was also loaded.\
(C) Interaction between CITED2 and ISL1 visualized by BiFC assays in undifferentiated E14/T ESC. Fluorescence emission (right panels) and morphological aspect of E14/T cells as observed in bright field (left panels) was examined 1 day after transfection and in embryoid bodies at D2 and D5 of differentiation.\
(D) Hep3B cells were transiently co-transfected with 40 ng of Mef2c-luc reporter, together with 100 ng of either myc-ISL1 expressing or empty control vector, and increasing amounts of a flag-CITED2-expressing plasmid (0, 50, and 100 ng) combined with the empty plasmid to achieve a total of 400 ng in each condition. The luciferase activity was normalized for the β-GALACTOSIDASE activity conferred by CMV-*lacZ* (100 ng). Relative luminescence units (RLU) are presented relative to values of the *Mef2c*-luc transfected with the control vectors set at 1.\
(E) Percentage of colonies with beating foci at D8, D10, and D12 in cultures derived from differentiation of E14/T ESC transfected individually or in combination with vectors expressing VEN-ISL1 and VEC-CITED2, or control vectors at D0.\
(F) Model for the role of CITED2 during cardiogenesis of ESC, as supported by the data from our study. CITED2 is required for the normal expression of mesoderm progenitor markers such as *Brachyury* and *Mesp1*. In addition, at this stage CITED2 contributes to the expression of *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5*, which are CPC markers. The overexpression of CITED2 triggers an increase of *Isl1*, *Nkx2.5*, *Gata4*, and *Tbx5* expression in undifferentiated ESC, which may favor cardiac differentiation. Finally, CITED2 and ISL1 proteins physically interact and cooperatively promote cardiac differentiation.\
Results in (D) and (E) are presented as the mean ± SEM of three independent biological experiments.](gr5){#fig5}
